SOM Biotech

About

SOM Biotech is a clinical-stage biopharmaceutical company based in Barcelona, Spain, founded in 2009. The company focuses on discovering and developing therapies for orphan diseases using its proprietary artificial intelligence platform, SOM AI PRO®. This innovative technology analyzes molecular field maps to identify new mechanisms of action, enabling accelerated drug discovery across various therapeutic areas. SOM Biotech has a multi-stage pipeline that includes its lead product, SOM3355, currently in Phase 2b development for chorea in Huntington's Disease. The company is also developing programs for Phenylketonuria, Niemann Pick Type C, and Parkinson's Disease, along with 20 additional orphan disease programs in early-stage development. SOM Biotech operates a hybrid business model, combining in-house drug development with strategic partnerships, offering services such as drug repurposing and AI-driven drug discovery to pharmaceutical companies and research institutions. The company has received recognition for its innovative contributions to R&D and has secured various grants and funding to support its initiatives.